On Friday, Shares of Bristol-Myers Squibb Co (NYSE:BMY), lost -2.62% to $61.07.
Bristol-Myers Squibb Company, declared a charitable donation to The Leukemia & Lymphoma Society (LLS). The donation will provide financial assistance for chronic myeloid leukemia (CML) patients who need assist paying for Polymerase Chain Reaction (PCR) testing, an important tool used in the diagnosis and monitoring of CML. The donation will also support LLS CML awareness activities focused on educating patients, caregivers and healthcare providers about the importance of continued monitoring with PCR testing.
“Routine PCR testing is critical because oncologists rely on the results to determine their patients’ clinical status of early and ongoing response to CML treatment and to assist detect when patients are potentially becoming resistant to treatment, which may allow for earlier intervention,” said Louis J. DeGennaro, LLS’s president and CEO. “Research indicates that early response to treatment and careful monitoring correlate with better overall survival rates.”
The PCR test is used both in the diagnosis of CML and to monitor for cancerous cells after treatment has begun. It is the most sensitive testing method accessible, with the ability to detect a single cancerous cell among one million healthy cells. Recommendations suggest that a CML patient should receive a PCR test every three months for the first three years after diagnosis, and every three to six months thereafter based on how well their treatment is working. The average cost of a PCR test is $345 and can be as high as $500 per test. The program will assist insured and uninsured patients with out-of-pocket costs for PCR testing. The donation will also fund national CML awareness activities that will be undertaken by LLS’s 56 chapters, in addition to grassroots efforts through local networks of patients, volunteers, and healthcare institutions.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
Shares of Cabot Corp (NYSE:CBT), declined -2.00% to $33.25, during its last trading session.
Cabot Corporation released its 2014/2015 Sustainability Report and third Global Reporting Initiative (GRI) Report highlighting the company’s sustainability progress as well as expanded and improved sustainability aims.
In the report, Cabot declares that it has joined the United Nations Global Compact (UNGC). Though a new endorser of the UNGC, Cabot has long fostered the spirit and intent of the 10 universally accepted UNGC principles in the areas of human rights, labor, environment and anti-corruption. These principles are a natural extension of Cabot’s values and business model, and the company continues to have strong programs that positively impact employees, customers, suppliers and the communities in which it operates.
Cabot Corporation operates as a specialty chemicals and performance materials company. The company offers carbon black, a form of elemental carbon used to enhance the physical properties of the systems and applications in which it is incorporated; and rubber blacks for use as a rubber reinforcing agent and performance additive in tires, hoses, belts, extruded profiles, and molded goods.
Finally, Net 1 UEPS Technologies Inc (NASDAQ:UEPS), ended its last trade with 3.79% gain, and closed at $19.98.
Net 1 UEPS Technologies, released results for the fourth quarter and full-year fiscal 2015.
Revenue not taking into account SASSA recovery, Fundamental net income, Fundamental net income not taking into account SASSA recovery, Fundamental earnings per share and Fundamental earnings per share not taking into account SASSA recovery are non-GAAP measures and are described below under “Use of Non-GAAP Measures — Fundamental net income and fundamental earnings per share.” See Attachment B for a reconciliation of GAAP net income to fundamental net income and earnings per share.
Revenue not taking into account SASSA recovery is Revenue earned during 2014 less about $26.6 million received from SASSA related to the recovery of additional implementation costs incurred during the beneficiary re-registration process in fiscal 2012 and 2013
Net 1 UEPS Technologies, Inc. provides payment solutions and transaction processing services for various industries in South Africa, South Korea, and internationally. The company develops and markets transaction-processing solutions that comprise its smart card-based alternative payment system for the unbanked and under-banked populations of developing economies, and for mobile transaction channels.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
